Cargando…

Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis

BACKGROUND: Adherence to adjuvant endocrine therapy (AET) for estrogen receptor-positive breast cancer remains suboptimal, which suggests that women are not getting the full benefit of the treatment to reduce breast cancer recurrence and mortality. The majority of studies on adherence to AET focus o...

Descripción completa

Detalles Bibliográficos
Autores principales: Farias, Albert J., Hansen, Ryan N., Zeliadt, Steven B., Ornelas, India J., Li, Christopher I., Thompson, Beti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978119/
https://www.ncbi.nlm.nih.gov/pubmed/27459660
http://dx.doi.org/10.18553/jmcp.2016.22.8.969
_version_ 1782447152133308416
author Farias, Albert J.
Hansen, Ryan N.
Zeliadt, Steven B.
Ornelas, India J.
Li, Christopher I.
Thompson, Beti
author_facet Farias, Albert J.
Hansen, Ryan N.
Zeliadt, Steven B.
Ornelas, India J.
Li, Christopher I.
Thompson, Beti
author_sort Farias, Albert J.
collection PubMed
description BACKGROUND: Adherence to adjuvant endocrine therapy (AET) for estrogen receptor-positive breast cancer remains suboptimal, which suggests that women are not getting the full benefit of the treatment to reduce breast cancer recurrence and mortality. The majority of studies on adherence to AET focus on identifying factors among those women at the highest levels of adherence and provide little insight on factors that influence medication use across the distribution of adherence. OBJECTIVE: To understand how factors influence adherence among women across low and high levels of adherence. METHODS: A retrospective evaluation was conducted using the Truven Health MarketScan Commercial Claims and Encounters Database from 2007-2011. Privately insured women aged 18-64 years who were recently diagnosed and treated for breast cancer and who initiated AET within 12 months of primary treatment were assessed. Adherence was measured as the proportion of days covered (PDC) over a 12-month period. Simultaneous multivariable quantile regression was used to assess the association between treatment and demographic factors, use of mail order pharmacies, medication switching, and out-of-pocket costs and adherence. The effect of each variable was examined at the 40th, 60th, 80th, and 95th quantiles. RESULTS: Among the 6,863 women in the cohort, mail order pharmacies had the greatest influence on adherence at the 40th quantile, associated with a 29.6% (95% CI = 22.2-37.0) higher PDC compared with retail pharmacies. Out-of-pocket cost for a 30-day supply of AET greater than $20 was associated with an 8.6% (95% CI = 2.8-14.4) lower PDC versus $0-$9.99. The main factors that influenced adherence at the 95th quantile were mail order pharmacies, associated with a 4.4% higher PDC (95% CI = 3.8-5.0) versus retail pharmacies, and switching AET medication 2 or more times, associated with a 5.6% lower PDC versus not switching (95% CI = 2.3-9.0). CONCLUSIONS: Factors associated with adherence differed across quantiles. Addressing the use of mail order pharmacies and out-of-pocket costs for AET may have the greatest influence on improving adherence among those women with low adherence.
format Online
Article
Text
id pubmed-4978119
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-49781192016-08-09 Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis Farias, Albert J. Hansen, Ryan N. Zeliadt, Steven B. Ornelas, India J. Li, Christopher I. Thompson, Beti J Manag Care Spec Pharm Research BACKGROUND: Adherence to adjuvant endocrine therapy (AET) for estrogen receptor-positive breast cancer remains suboptimal, which suggests that women are not getting the full benefit of the treatment to reduce breast cancer recurrence and mortality. The majority of studies on adherence to AET focus on identifying factors among those women at the highest levels of adherence and provide little insight on factors that influence medication use across the distribution of adherence. OBJECTIVE: To understand how factors influence adherence among women across low and high levels of adherence. METHODS: A retrospective evaluation was conducted using the Truven Health MarketScan Commercial Claims and Encounters Database from 2007-2011. Privately insured women aged 18-64 years who were recently diagnosed and treated for breast cancer and who initiated AET within 12 months of primary treatment were assessed. Adherence was measured as the proportion of days covered (PDC) over a 12-month period. Simultaneous multivariable quantile regression was used to assess the association between treatment and demographic factors, use of mail order pharmacies, medication switching, and out-of-pocket costs and adherence. The effect of each variable was examined at the 40th, 60th, 80th, and 95th quantiles. RESULTS: Among the 6,863 women in the cohort, mail order pharmacies had the greatest influence on adherence at the 40th quantile, associated with a 29.6% (95% CI = 22.2-37.0) higher PDC compared with retail pharmacies. Out-of-pocket cost for a 30-day supply of AET greater than $20 was associated with an 8.6% (95% CI = 2.8-14.4) lower PDC versus $0-$9.99. The main factors that influenced adherence at the 95th quantile were mail order pharmacies, associated with a 4.4% higher PDC (95% CI = 3.8-5.0) versus retail pharmacies, and switching AET medication 2 or more times, associated with a 5.6% lower PDC versus not switching (95% CI = 2.3-9.0). CONCLUSIONS: Factors associated with adherence differed across quantiles. Addressing the use of mail order pharmacies and out-of-pocket costs for AET may have the greatest influence on improving adherence among those women with low adherence. Academy of Managed Care Pharmacy 2016-08 /pmc/articles/PMC4978119/ /pubmed/27459660 http://dx.doi.org/10.18553/jmcp.2016.22.8.969 Text en © 2016, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research
Farias, Albert J.
Hansen, Ryan N.
Zeliadt, Steven B.
Ornelas, India J.
Li, Christopher I.
Thompson, Beti
Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis
title Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis
title_full Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis
title_fullStr Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis
title_full_unstemmed Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis
title_short Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis
title_sort factors associated with adherence to adjuvant endocrine therapy among privately insured and newly diagnosed breast cancer patients: a quantile regression analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978119/
https://www.ncbi.nlm.nih.gov/pubmed/27459660
http://dx.doi.org/10.18553/jmcp.2016.22.8.969
work_keys_str_mv AT fariasalbertj factorsassociatedwithadherencetoadjuvantendocrinetherapyamongprivatelyinsuredandnewlydiagnosedbreastcancerpatientsaquantileregressionanalysis
AT hansenryann factorsassociatedwithadherencetoadjuvantendocrinetherapyamongprivatelyinsuredandnewlydiagnosedbreastcancerpatientsaquantileregressionanalysis
AT zeliadtstevenb factorsassociatedwithadherencetoadjuvantendocrinetherapyamongprivatelyinsuredandnewlydiagnosedbreastcancerpatientsaquantileregressionanalysis
AT ornelasindiaj factorsassociatedwithadherencetoadjuvantendocrinetherapyamongprivatelyinsuredandnewlydiagnosedbreastcancerpatientsaquantileregressionanalysis
AT lichristopheri factorsassociatedwithadherencetoadjuvantendocrinetherapyamongprivatelyinsuredandnewlydiagnosedbreastcancerpatientsaquantileregressionanalysis
AT thompsonbeti factorsassociatedwithadherencetoadjuvantendocrinetherapyamongprivatelyinsuredandnewlydiagnosedbreastcancerpatientsaquantileregressionanalysis